MajesTEC 3 Survival Analysis Shows Durable Myeloma Control

Company Johnson & Johnson Event Type Clinical Trial Survival Analysis Modality Bispecific Antibody + CD38 Monoclonal Antibody Combination Asset Teclistamab + Daratumumab Target BCMA / CD3 / CD38 Disease Area Relapsed or Refractory Multiple Myeloma Summary Johnson & Johnson released additional analyses of the randomized…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline